Group 1 - The core viewpoint of the articles indicates that despite a decline in performance in the first half of 2025 compared to the same period in 2024, the company shows resilience in its operations, with a slight overall decrease in annual performance compared to 2024 [1] - The number of IVF cycles in the Greater China region is expected to improve, with a reduction in the decline from -5.2% in the first three quarters of 2024 to -1.4% for the entire year of 2025 [1] - The flagship hospital in Chengdu has shown significant improvement, with IVF cycles turning from a decline of -1.9% in the first three quarters of 2025 to a growth of 1.3% for the entire year [1] Group 2 - Looking ahead to 2026 and beyond, the company plans to enhance clinical treatment outcomes, patient care quality, and service supply levels while accelerating the upgrade of core reproductive medical technologies [2] - The company aims to deepen research innovation and clinical translation in reproductive medicine, optimize medical processes, and improve digital service experiences [2] - The company will leverage national fertility support policies and industry development opportunities to strengthen its competitiveness and provide high-quality medical services, ultimately creating long-term stable value for shareholders [2]
锦欣生殖(01951)2025年IVF取卵周期数整体降幅进一步收窄至-1.4%